Journal of thrombosis and haemostasis : JTH
-
J. Thromb. Haemost. · Dec 2018
Multicenter Study Observational StudyDetermining the minimal clinically important difference for the PEmbQoL questionnaire, a measure of pulmonary embolism-specific quality of life.
Essentials The minimal clinically important difference (MCID) for PEmbQoL has not yet been determined. We estimated the MCID for PEmbQoL and its subscales via anchor- and distribution-based approaches. Our results indicate that MCID for PEmbQoL appears to be 15 points. ⋯ Using both anchor- and distribution-based approaches, the MCID for PEmbQoL appears to be 15 points. Based on this MCID, 42%, 59%, 66% and 75% of patients experienced at least one MCID unit of improvement in PEmbQoL from baseline to 1, 3, 6 and 12 months, respectively. Conclusion Our results provide new information on the MCID of PEmbQoL, a PE-specific QOL questionnaire that can be used by researchers and clinicians to measure and interpret changes in PE-specific QOL over time, or as an outcome in clinical trials.
-
J. Thromb. Haemost. · Oct 2018
Multicenter StudyLongitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism.
Essentials Inflammatory and cardiac diseases are associated with increased venous thromboembolism (VTE) risk. Our prospective study assessed rise in inflammatory or cardiac biomarkers and VTE risk. A greater 6-year rise in N-terminal natriuretic peptide is associated with increased VTE incidence. Volume overload or impending cardiac disease may contribute to VTE occurrence.
-
J. Thromb. Haemost. · Sep 2018
Multicenter StudyRisk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults.
Essentials Risk factors of bleeding in adult immune thrombocytopenia are not known. This multicenter study assessed risk factors of bleeding at immune thrombocytopenia onset. Platelet count thresholds associated with bleeding were < 20 × 109 L-1 and < 10 × 109 L-1. Exposure to anticoagulants was a major risk factor of severe bleeding.
-
J. Thromb. Haemost. · Jul 2018
Multicenter Study Comparative StudyPrediction of short-term prognosis in elderly patients with acute pulmonary embolism: validation of the RIETE score.
Essentials The RIETE score was derived to predict 10-day adverse outcomes in acute pulmonary embolism (PE). We externally validated the RIETE score in a prospective cohort of patients with PE. The RIETE score classified fewer patients as low-risk than currently recommended scores. The RIETE score was not superior to other scores in predicting 10-day adverse outcomes.
-
J. Thromb. Haemost. · Jun 2018
Randomized Controlled Trial Multicenter Study Comparative StudyClinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.
Essentials Cancer patients receiving anticoagulants for venous thromboembolism have an elevated bleeding risk. This secondary analysis of CATCH assessed characteristics of clinically relevant bleeding (CRB). CRB occurs in 15% of cancer patients with thrombosis using therapeutic doses of anticoagulation. After multivariate analysis, risk factors for CRB were age >75 years and intracranial malignancy.